Back

Beneficial SGLT2 inhibitors (SGLT2In) effects in patients with left ventricular assist device (LVAD)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Advanced heart failure Ventricular Assist Devices ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Przemyslaw Leszek

National Institute of Cardiology, Warsaw (Poland)

7 More presentations in this session

Presentation thumbnail
Association of left ventricular fibrosis with hemodynamics and myocardial remodeling among patients undergoing left ventricular assist device implant
Doctor G. Gallone (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Comparative study of the effects of left ventricular pacing compared to biventricular pacing on indices of cardiac function and clinical status of heart failure patients READAPT study
Doctor P. Dilaveris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Improved right ventricular systolic function after cardiac resynchronization therapy in heart failure patients
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video
Presentation thumbnail
The role of multipoint left ventricular pacing compared to optimized cardiac resynchronization therapy on long-term follow-up in chronic heart failure patients
Doctor P. Dilaveris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Factors associated with successful treatment with temporary right ventricular assist devices for right ventricular failure in recipients of HeartMate 3 left ventricular assist device
Doctor M. Lorente-Ros (Washington, DC, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on myocardial work in patients with heart failure with reduced ejection fraction
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors for the treatment of single ventricle circulatory failure in adults with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources